Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

In vitro testing of combined hydroxychloroquine and azithromycin on SARS-CoV-2 shows synergistic effect
Julien Andréani, Marion Le Bideau, Isabelle Duflot, et al.
Microbial Pathogenesis (2020) Vol. 145, pp. 104228-104228
Open Access | Times Cited: 303

Showing 1-25 of 303 citing articles:

COVID-19: Immunology and treatment options
Susanna Felsenstein, Jenny A. Herbert, Paul McNamara, et al.
Clinical Immunology (2020) Vol. 215, pp. 108448-108448
Open Access | Times Cited: 657
Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19
Samia Arshad, Paul E. Kilgore, Zohra Chaudhry, et al.
International Journal of Infectious Diseases (2020) Vol. 97, pp. 396-403
Open Access | Times Cited: 556
Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille, France
Matthieu Million, Jean‐Christophe Lagier, Philippe Gautret, et al.
Travel Medicine and Infectious Disease (2020) Vol. 35, pp. 101738-101738
Open Access | Times Cited: 479
Aging, Immunity, and COVID-19: How Age Influences the Host Immune Response to Coronavirus Infections?
Varnica Bajaj, Nirupa Gadi, Allison P. Spihlman, et al.
Frontiers in Physiology (2021) Vol. 11
Open Access | Times Cited: 431
Effect of hydroxychloroquine with or without azithromycin on the mortality of coronavirus disease 2019 (COVID-19) patients: a systematic review and meta-analysis
Thibault Fiolet, Anthony Guihur, Mathieu E. Rebeaud, et al.
Clinical Microbiology and Infection (2020) Vol. 27, Iss. 1, pp. 19-27
Open Access | Times Cited: 295
Outcomes of 3,737 COVID-19 patients treated with hydroxychloroquine/azithromycin and other regimens in Marseille, France: A retrospective analysis
Jean‐Christophe Lagier, Matthieu Million, Philippe Gautret, et al.
Travel Medicine and Infectious Disease (2020) Vol. 36, pp. 101791-101791
Open Access | Times Cited: 254
Azithromycin in the treatment of COVID-19: a review
Daniel Echeverría-Esnal, Clara Martín‐Ontiyuelo, María Eugenia Navarrete-Rouco, et al.
Expert Review of Anti-infective Therapy (2020) Vol. 19, Iss. 2, pp. 147-163
Open Access | Times Cited: 233
Self-medication practices during the COVID-19 pandemic among the adult population in Peru: A cross-sectional survey
Jean Franco Quispe-Cañari, Evelyn Fidel-Rosales, Diego Manrique, et al.
Saudi Pharmaceutical Journal (2020) Vol. 29, Iss. 1, pp. 1-11
Open Access | Times Cited: 231
Antibiotics and antimicrobial resistance in the COVID-19 era: Perspective from resource-limited settings
Mentor Ali Ber Lucien, Michael F. Canarie, Paul E. Kilgore, et al.
International Journal of Infectious Diseases (2021) Vol. 104, pp. 250-254
Open Access | Times Cited: 223
Hyperglycemia, hydroxychloroquine, and the COVID‐19 pandemic
Adam Brufsky
Journal of Medical Virology (2020) Vol. 92, Iss. 7, pp. 770-775
Open Access | Times Cited: 198
Clinical Pharmacology Perspectives on the Antiviral Activity of Azithromycin and Use in COVID‐19
Bharat Damle, Manoli Vourvahis, Erjian Wang, et al.
Clinical Pharmacology & Therapeutics (2020) Vol. 108, Iss. 2, pp. 201-211
Open Access | Times Cited: 172
Monocytes and Macrophages, Targets of Severe Acute Respiratory Syndrome Coronavirus 2: The Clue for Coronavirus Disease 2019 Immunoparalysis
Asma Boumaza, Laëtitia Gay, Soraya Mezouar, et al.
The Journal of Infectious Diseases (2021) Vol. 224, Iss. 3, pp. 395-406
Open Access | Times Cited: 161
Patient Characteristics and Outcomes of 11 721 Patients With Coronavirus Disease 2019 (COVID-19) Hospitalized Across the United States
Michael Fried, Julie M. Crawford, Andrea R. Mospan, et al.
Clinical Infectious Diseases (2020) Vol. 72, Iss. 10, pp. e558-e565
Open Access | Times Cited: 147
Natural history of COVID-19 and therapeutic options
Philippe Gautret, Matthieu Million, Pierre‐André Jarrot, et al.
Expert Review of Clinical Immunology (2020) Vol. 16, Iss. 12, pp. 1159-1184
Closed Access | Times Cited: 143
Azithromycin in viral infections
Madeleine Oliver, Timothy S.C. Hinks
Reviews in Medical Virology (2020) Vol. 31, Iss. 2
Open Access | Times Cited: 142
Cytokine Storm: The Primary Determinant for the Pathophysiological Evolution of COVID-19 Deterioration
Ruirong Chen, Zhien Lan, Jujian Ye, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 138
A review of potential suggested drugs for coronavirus disease (COVID-19) treatment
Parastoo Tarighi, S. Eftekhari, Milad Chizari, et al.
European Journal of Pharmacology (2021) Vol. 895, pp. 173890-173890
Open Access | Times Cited: 116
Therapeutics for COVID-19
Sima S. Toussi, Jennifer Hammond, Brian S. Gerstenberger, et al.
Nature Microbiology (2023) Vol. 8, Iss. 5, pp. 771-786
Open Access | Times Cited: 66
Progress in Developing Inhibitors of SARS-CoV-2 3C-Like Protease
Qingxin Li, CongBao Kang
Microorganisms (2020) Vol. 8, Iss. 8, pp. 1250-1250
Open Access | Times Cited: 119
Azithromycin for COVID-19: More Than Just an Antimicrobial?
Nathalie Bleyzac, Sylvain Goutelle, Laurent Bourguignon, et al.
Clinical Drug Investigation (2020) Vol. 40, Iss. 8, pp. 683-686
Open Access | Times Cited: 116
The immuno-oncological challenge of COVID-19
Lisa Derosa, Cléa Melenotte, Frank Griscelli, et al.
Nature Cancer (2020) Vol. 1, Iss. 10, pp. 946-964
Open Access | Times Cited: 116
Potential Antiviral Options against SARS-CoV-2 Infection
Aleksandr Ianevski, Rouan Yao, Mona Høysæter Fenstad, et al.
Viruses (2020) Vol. 12, Iss. 6, pp. 642-642
Open Access | Times Cited: 111
Drug Discovery Strategies for SARS-CoV-2
Zeenat A. Shyr, Kirill Gorshkov, Catherine Z. Chen, et al.
Journal of Pharmacology and Experimental Therapeutics (2020) Vol. 375, Iss. 1, pp. 127-138
Open Access | Times Cited: 105
COVID-19 outpatients: early risk-stratified treatment with zinc plus low-dose hydroxychloroquine and azithromycin: a retrospective case series study
Roland Derwand, Martin Scholz, Vladimir Zelenko
International Journal of Antimicrobial Agents (2020) Vol. 56, Iss. 6, pp. 106214-106214
Open Access | Times Cited: 102
Antimalarial artemisinin-based combination therapies (ACT) and COVID-19 in Africa: In vitro inhibition of SARS-CoV-2 replication by mefloquine-artesunate
Mathieu Gendrot, Isabelle Duflot, Manon Boxberger, et al.
International Journal of Infectious Diseases (2020) Vol. 99, pp. 437-440
Open Access | Times Cited: 100
Page 1 - Next Page

Scroll to top